Hydroxyurea has many characteristics of an ideal drug for sickle cell anemia (SCA) and provides therapeutic benefit through multiple mechanisms of action
Treatment
Taken together, our findings suggest that many miRNAs regulated by GCH1 may be involved in microglial activation, which may provide new potential targets for
4 Jinyu West Road, Rencheng District, Jining City, Shandong Province
Early proof of principle studies were followed by prospective phase 1/2 These findings confirmed that the SCA patients indeed exhibit indication of red blood cell lysis and activation of compensatory mechanisms and suggest that hydroxyurea therapy may be associated Hydroxyurea is one of the earliest drugs that showed promise in the management of haemoglobinopathies that include β-thalassaemia and sickle cell disease
It is also useful to increase fetal hemoglobin concentration, thus reducing the frequency of severe crisis and reducing the necessity for
This topic review discusses hydroxyurea
31 In a cohort of children with SCA, hydroxyurea decreased the rate of recurrent stroke compared with no therapy (Table 2)
However, the USFDA approved hydroxyurea for pediatric patients two years and above only in 2017 (based on the ESCORT HU trial)
Higher levels of fetal hemoglobin (HbF) diminish deoxygenated sickle globin polymerization in Evaluation of oxidative stress markers in neutrophils of patients with sickle cell anemia (SCA) treated or not with hydroxyurea (HU)
0 g/day)
Oxidative stress contributes to the pathophysiology of sickle cell anemia (SCA)
[ 4 ] Hydroxyurea at MTD is associated with lower malaria incidence in SCA through incompletely defined mechanisms, but treatment-associated mild myelosuppression with ANC <3
Hydroxyurea is an antimetabolite that is used in the treatment of cancer and to stimulate fetal hemoglobin production in sickle cell disease
Introduction
Several studies have demonstrated the efficacy of hydroxyurea in ameliorating disease pathophysiology